How Much Weight Can You Lose on Obeda? Realistic Results Explained

One of the first things people want to know before starting Obeda is: how much weight will I actually lose?

It is the right question. Setting honest expectations protects you from disappointment and helps you plan realistically. The answer is based on clinical trials of semaglutide (Obeda itself has no weight-loss trials) -- and individual results vary more than most people expect.

Obeda is Dr. Reddy's semaglutide injection, launched in India in March 2026 and approved by DCGI for type 2 diabetes. It comes in 2 mg and 4 mg pens, each giving at least four weekly doses, which corresponds to weekly doses of up to 1 mg. Using it only for weight loss is off-label, so discuss this with your doctor.

Important: Always consult your healthcare provider before starting any medication. This article is for informational purposes only.

What the Clinical Trials Show

Obeda contains semaglutide, which has been studied in one of the largest weight-loss drug trial programmes ever run (the STEP trials), as well as in the SUSTAIN trials in type 2 diabetes.

STEP 1 (the best-known weight-loss trial):

• Participants: Adults without diabetes with a BMI of 30 or more, or 27 or more with a weight-related condition
• Drug: Semaglutide 2.4mg weekly (Wegovy dose -- higher than Obeda's 1mg maximum)
• Duration: 68 weeks
• Average weight loss: 14.9% of body weight
• Percentage losing 10%+ of body weight: 69%
• Percentage losing 15%+ of body weight: 50%

At Obeda's 1mg dose (adults with type 2 diabetes):

• STEP 2 (68 weeks): semaglutide 1mg -- average weight loss about 7% (versus 9.6% on 2.4mg and 3.4% on placebo)
• SUSTAIN FORTE (40 weeks): semaglutide 1mg -- average weight loss about 6 kg (6.9 kg on 2mg)

There are no trials of semaglutide 1mg for weight loss in people without diabetes, who tend to lose more than people with diabetes. These are averages. The spread is wide.

Real-World Weight Loss Estimates by Starting Weight

This table simply converts percentages into kilograms. It is not a prediction for any individual.

In STEP 2, the average with semaglutide 1mg in type 2 diabetes was about 7% over 68 weeks, alongside a lifestyle programme. A healthy diet and regular activity support results, but no one can promise a specific number.

Timeline: Weight Loss by Month

There is no month-by-month data for Obeda. In semaglutide trials, the first weeks are spent at low starting doses (0.25mg, then 0.5mg), so early weight loss is usually small. Loss tends to pick up once you reach your maintenance dose, then slows and levels off over the following months, often with plateaus along the way. See the Obeda results week-by-week guide for a detailed breakdown.

What Determines How Much You Lose?

Results vary significantly between patients. The key factors:

1. Starting Weight

Patients with higher starting weights tend to lose more in absolute kilograms, even if the percentage is similar.

2. Diet Quality

This is the biggest modifiable factor. A protein-rich, lower-calorie diet supports weight loss and helps protect muscle. Obeda reduces appetite -- it does not change what you eat. Eating protein-rich, whole foods amplifies the results. Knowing what to eat while taking Obeda is essential.

3. Dose Reached

In trials, semaglutide 1mg led to somewhat more weight loss on average than 0.5mg. Whether to increase your dose is your doctor's decision, based on your blood sugar, tolerability and goals.

4. Consistency

Skipping doses, stopping and restarting, or stopping early all reduce cumulative results significantly. Semaglutide builds its effect over time.

5. Activity Level

Exercise amplifies weight loss and, critically, helps preserve muscle mass during fat loss. Regular moderate activity, such as brisk walking most days plus some strength training, supports muscle and overall health.

6. Individual Biology

Genetics, gut microbiome, insulin sensitivity, and hormonal factors all influence response. Some people are strong responders; others see below-average results despite good adherence. This is true of all weight-loss interventions.

What Does 5-10% Weight Loss Actually Mean?

A 5-10% reduction in body weight may sound modest. But the metabolic and health impact can be meaningful.

A 5-10% reduction in body weight is commonly linked with:

• Better blood sugar control
• Lower blood pressure
• Improved cholesterol and triglyceride levels
• Less strain on knees and other joints
• Improved energy, mobility, and quality of life

Even a few kilograms lost and kept off can make a real difference to your health.

Managing Expectations: What Obeda Is Not

Obeda is not a cosmetic drug for people who want to lose a few kilos. It is a prescription medicine approved in India for type 2 diabetes, and any use for weight management should be planned with your doctor.

If you expect to lose 30 kg in 3 months, you will be disappointed. A loss of around 5-10% of your starting weight over a year or more, with better blood sugar and overall health, is a more realistic expectation at Obeda's doses -- though some people lose more and some less.

Before-and-after photos on social media often cherry-pick exceptional responders or combine multiple interventions. Average results are meaningful but not dramatic by social media standards.

How Weight Easy Pushes Your Results Higher

Results on semaglutide vary widely, and diet, activity and consistency are the parts you can influence.

Weight Easy is designed to help with those parts. Personalised diet plans built around GLP-1 medication, habit coaching, side effect management, and progress tracking -- all aimed at helping you stay consistent with the habits that support your treatment.

If you are starting Obeda, the right support can make a significant difference. Weight Easy helps you stay consistent and manage side effects.

The Bottom Line

In trials of semaglutide 1mg (Obeda's highest dose) in adults with type 2 diabetes, average weight loss was about 6-7% over 40 to 68 weeks -- about 5-6 kg at an 80kg starting weight, or 6-7 kg at 100kg. Higher-dose semaglutide (2.4mg, Wegovy) produced larger losses in people without diabetes, but that is not the dose Obeda provides.

Individual results vary widely. Set honest expectations, keep up healthy eating and activity, stay consistent, and review your progress with your doctor.

Get urgent medical help for severe, persistent abdominal pain that may spread to your back, pain in the upper right abdomen with fever or yellow skin or eyes, vomiting or diarrhoea that stops you keeping fluids down, a serious allergic reaction, or low blood sugar symptoms if you also take insulin or a sulfonylurea.

Consult your healthcare provider before starting any medication.

Sources

• STEP 1 semaglutide trial — PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/
• STEP 2 trial (semaglutide 2.4mg vs 1mg in type 2 diabetes, Lancet 2021) — PubMed: https://pubmed.ncbi.nlm.nih.gov/33667417/
• SUSTAIN FORTE trial (semaglutide 2mg vs 1mg, Lancet Diabetes Endocrinol 2021) — PubMed: https://pubmed.ncbi.nlm.nih.gov/34293304/
• STEP 1 trial extension (weight regain after stopping, Diabetes Obes Metab 2022) — PubMed: https://pubmed.ncbi.nlm.nih.gov/35441470/
• BioSpectrum India — Dr. Reddy's launches DCGI-approved semaglutide injection Obeda for type 2 diabetes (March 2026): https://www.biospectrumindia.com/public/news/73/27524/dr-reddys-laboratories-announces-launch-of-dcgi-approved-semaglutide-injection-obeda-for-type-2-diabetes.html
• Central Drugs Standard Control Organisation (CDSCO): https://cdsco.gov.in/opencms/opencms/en/Home/
• MedicalDialogues — India semaglutide market and brand launch context: https://medicaldialogues.in/news/industry/pharma/indias-semaglutide-market-set-for-generic-boom-as-patents-expire-over-50-brands-lined-up-for-launch-see-full-list-165838
• Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf